Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + mitoxantrone is a combination chemotherapy regimen consisting of two small molecule antineoplastic agents. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase, leading to cell cycle arrest and apoptosis. Mitoxantrone is an anthracenedione that intercalates into DNA, causing crosslinks and strand breaks, and inhibits topoisomerase II, resulting in cytotoxicity. This combination has been studied as a treatment for metastatic breast cancer (as second- or third-line therapy) and for relapsed or refractory acute leukemia. The regimen has demonstrated objective response rates in these settings with manageable toxicity profiles[1][4].
- Other names
- gemcitabine/mitoxantronegemcitabine and mitoxantronegemcitabine hydrochloride + mitoxantrone hydrochloride
02
Targets
TOP2A (DNA topoisomerase II)DNA polymerase familyDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + mitoxantrone.